WebJunction Course Catalog

Hybridoma technology is a method used to produce large amount of monoclonal antibodies, which can be widely used in biological and medical research, disease prevention, diagnostic and treatment, and clinical applications. Monoclonal antibodies produced by hybridoma technology always retain their native structure. Once stablized, hybridomas can offer unlimited quantities of consistent, homogenized antibodies in a cost-effective manner. This is perfect for further research and application.

Hybridoma technology is mainly based on three key technologies and steps.

1. Animal immunity. Before the preparation of hybridoma cells, a target antigen is used to immunize animals, usually mice, to elicit an immune response.
2. Cell fusion. B lymphocytes, which have the capability to produce antibodies against the injected antigen, are harvested from immunized animals and then fused with an immortal myeloma cell line. The hybrid cell lines are called hybridomas. They are immortalized cells with the ability to produce unlimited quantities of monoclonal antibodies.
3. Hybridoma screening. Firstly, optimal selective media, such as HAT media, are used to remove unfused cells. Secondly, the specific antibody-producing hybridomas of interest need to be identified.